BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22951114)

  • 1. A frozen analogue approach to aminopyridinylimidazoles leading to novel and promising p38 MAP kinase inhibitors.
    Selig R; Goettert M; Schattel V; Schollmeyer D; Albrecht W; Laufer S
    J Med Chem; 2012 Oct; 55(19):8429-39. PubMed ID: 22951114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.
    Laufer SA; Hauser DR; Domeyer DM; Kinkel K; Liedtke AJ
    J Med Chem; 2008 Jul; 51(14):4122-49. PubMed ID: 18578517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.
    Laufer SA; Wagner GK; Kotschenreuther DA; Albrecht W
    J Med Chem; 2003 Jul; 46(15):3230-44. PubMed ID: 12852754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking.
    Ravindra GK; Achaiah G; Sastry GN
    Eur J Med Chem; 2008 Apr; 43(4):830-8. PubMed ID: 17706839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase.
    Kim DK; Lim JH; Lee JA; Dewang PM
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4006-10. PubMed ID: 18571921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the hydrogen bonding heteroatom-Lys53 interaction between the p38alpha mitogen-activated protein (MAP) kinase and pyridinyl-substituted 5-membered heterocyclic ring inhibitors.
    Abu Thaher B; Koch P; Schattel V; Laufer S
    J Med Chem; 2009 Apr; 52(8):2613-7. PubMed ID: 19301816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tri- and tetrasubstituted imidazoles as p38α mitogen-activated protein kinase inhibitors.
    Laufer S; Hauser D; Stegmiller T; Bracht C; Ruff K; Schattel V; Albrecht W; Koch P
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6671-5. PubMed ID: 20934337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
    Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
    J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of regioisomers in a series of N-substituted pyridin-4-yl imidazole derivatives by regiospecific synthesis, GC/MS, and 1H NMR.
    Wagner GK; Kotschenreuther D; Zimmermann W; Laufer SA
    J Org Chem; 2003 May; 68(11):4527-30. PubMed ID: 12762762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-Acylaminopyridin-4-ylimidazoles as p38 MAP kinase inhibitors: Design, synthesis, and biological and metabolic evaluations.
    Ziegler K; Hauser DR; Unger A; Albrecht W; Laufer SA
    ChemMedChem; 2009 Nov; 4(11):1939-48. PubMed ID: 19731280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]pyridin-2-one-Based p38 MAP Kinase Inhibitors: Part 1.
    Kaieda A; Takahashi M; Fukuda H; Okamoto R; Morimoto S; Gotoh M; Miyazaki T; Hori Y; Unno S; Kawamoto T; Tanaka T; Itono S; Takagi T; Sugimoto H; Okada K; Snell G; Bertsch R; Nguyen J; Sang BC; Miwatashi S
    ChemMedChem; 2019 May; 14(10):1022-1030. PubMed ID: 30945818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Theoretical and experimental design of atypical kinase inhibitors: application to p38 MAP kinase.
    McClure KF; Abramov YA; Laird ER; Barberia JT; Cai W; Carty TJ; Cortina SR; Danley DE; Dipesa AJ; Donahue KM; Dombroski MA; Elliott NC; Gabel CA; Han S; Hynes TR; Lemotte PK; Mansour MN; Marr ES; Letavic MA; Pandit J; Ripin DB; Sweeney FJ; Tan D; Tao Y
    J Med Chem; 2005 Sep; 48(18):5728-37. PubMed ID: 16134941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase.
    Koeberle SC; Fischer S; Schollmeyer D; Schattel V; Grütter C; Rauh D; Laufer SA
    J Med Chem; 2012 Jun; 55(12):5868-77. PubMed ID: 22676210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IRAK-4 inhibitors. Part II: a structure-based assessment of imidazo[1,2-a]pyridine binding.
    Buckley GM; Ceska TA; Fraser JL; Gowers L; Groom CR; Higueruelo AP; Jenkins K; Mack SR; Morgan T; Parry DM; Pitt WR; Rausch O; Richard MD; Sabin V
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3291-5. PubMed ID: 18482836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The identification of pyrazolo[1,5-a]pyridines as potent p38 kinase inhibitors.
    Cheung M; Harris PA; Badiang JG; Peckham GE; Chamberlain SD; Alberti MJ; Jung DK; Harris SS; Bramson NH; Epperly AH; Stimpson SA; Peel MR
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5428-30. PubMed ID: 18818075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, p38α MAP kinase inhibition, anti-inflammatory activity, and molecular docking studies of 1,2,4-triazole-based benzothiazole-2-amines.
    Tariq S; Alam O; Amir M
    Arch Pharm (Weinheim); 2018 Apr; 351(3-4):e1700304. PubMed ID: 29611883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unexpected reaction of 2-alkylsulfanylimidazoles to imidazol-2-ones: pyridinylimidazol-2-ones as novel potent p38alpha mitogen-activated protein kinase inhibitors.
    Koch P; Laufer S
    J Med Chem; 2010 Jun; 53(12):4798-802. PubMed ID: 20481631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissection of the recognition properties of p38 MAP kinase. Determination of the binding mode of a new pyridinyl-heterocycle inhibitor family.
    Soliva R; Gelpí JL; Almansa C; Virgili M; Orozco M
    J Med Chem; 2007 Jan; 50(2):283-93. PubMed ID: 17228870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach.
    Badrinarayan P; Sastry GN
    J Mol Graph Model; 2012 Apr; 34():89-100. PubMed ID: 22306417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aza-analogue dibenzepinone scaffolds as p38 mitogen-activated protein kinase inhibitors: design, synthesis, and biological data of inhibitors with improved physicochemical properties.
    Karcher SC; Laufer SA
    J Med Chem; 2009 Mar; 52(6):1778-82. PubMed ID: 19253982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.